Rose McNulty

The study provides proof of principle for a novel approach to early detection of ovarian cancer based on an assessment of genomic instability patterns in DNA from Papanicolaou (Pap) smears.

The January 2024 guidelines update also changed mirvetuximab soravtansine plus bevacizumab from a category 2B recommendation to a category 2A recommendation for platinum-resistant, FRα-expressing tumors.

Molly Mendenhall, BSN, RN, director of quality and compliance at Oncology Hematology Care, Inc (OHC), discussed a 1-year quality improvement project implemented by OHC to standardize comprehensive biomarker testing in patients with non–small cell lung cancer (NSCLC).

In a systematic review and meta-analysis, real-time continuous glucose monitoring (CGM) demonstrated benefits in terms of time in range, hypoglycemia, and hyperglycemia among patients with type 1 diabetes (T1D).

A real-world study found that patients treated with Bruton tyrosine kinase inhibitors had lower rates of treatment discontinuation and health care resource utilization compared with other first- and second-line treatment regimens.

A study of adolescents with type 1 diabetes (T1D) found that real-time continuous glucose monitoring (CGM) with a predictive hypoglycemia alarm reduced the time spent below range.

Michael Gieske, MD, director of lung cancer screening at St. Elizabeth Health Care, speaks to the success of the Rural Appalachian Lung Cancer Screening Initiative, along with challenges to implementing increased lung cancer screening.

An early-phase, dose-escalation study of a hypofractionated approach to concurrent chemoradiation using an an adaptive stereotactic ablative radiotherapy (SABR) boost showed promising results in patients with locally advanced, unresectable non­­–small cell lung cancer (NSCLC).

Findings from the phase 3 SEQUOIA trial favored zanubrutinib over bendamustine plus rituximab in most biomarker-based subgroups of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) without deletion of the 17p chromosome.

Margaret Liang, MD, MSHPM, gynecologic oncologist and health services researcher and director, Gynecologic Oncology Fellowship Program, Cedars-Sinai Cancer Center, discusses financial toxicity in cancer care and how institutions can help alleviate the financial burden for patients.

A Finnish study found maternal type 1 diabetes (T1D) to be associated with a significantly higher risk of any congenital heart defect (CHD) in offspring, and that maternal overweight or obesity was associated with certain CHDs in offspring.

Melinda C. Aldrich, PhD, MPH, associate professor in the departments of medicine, thoracic surgery, and biomedical informatics at Vanderbilt University, discussed recently updated lung screening guidelines from the American Cancer Society and the importance of equity across populations as new guidelines are developed.

An abstract presented at the 2023 American Society of Hematology Annual Meeting and Exposition suggests that patients with chronic lymphocytic leukemia (CLL) treated in the era of novel agents might be less likely to experience Richter transformation compared with those treated prior to this era.

Michael Gieske, MD, director of lung cancer screening at St. Elizabeth Health Care, discusses disparities in lung cancer incidence and mortality that the Rural Appalachian Lung Cancer Screening Initiative aims to address.

The most-read content from the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting including the latest findings in ongoing clinical trials, a panel discussion on Medicare oncology payment models, and the importance of alignment between clinicians and payers on clinical pathways.

In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.

In recently published data from the phase 3 PROTECT trial, teplizumab slowed the progression of type 1 diabetes in children and adolescents.

The most-read articles from the 2023 European Hematology Association (EHA) Annual Meeting covered the most up-to-date treatment strategies for hematological malignancies, racial disparities in treatment patterns for blood cancers, and updates on immunotherapy as a tool in hematologic oncology.

Data presented at the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition highlighted improvements in patient-reported outcomes (PROs) with ciltacabtagene autoleucel (cilta-cel) in multiple myeloma (MM).

Our top-read type 1 diabetes articles of 2023 covered increases in rates of pediatric diabetes early in the COVID-19 pandemic, novel therapies for T1D, and links between patient characteristics and T1D outcomes.

Our most-read oncology content of 2023 included meeting coverage, research on an algorithm using patient-reported outcomes to predict hospital visits, and the launch of an National Comprehensive Cancer Network pilot project aiming to measure health equity.

Mark A. Socinski, MD, executive director at AdventHealth Cancer Institute, discussed the emergence of targeted therapies for lung cancer and their ongoing impact on outcomes for certain patients.

Real-world data presented at the 2023 American Society of Hematology Annual Meeting and Exposition showed similar toxicity profiles and outcomes among older and younger patients with multiple myeloma (MM) treated with teclistamab.

The most-read content from the 2023 American Society of Hematology Annual Meeting and Exposition included the latest in treating hematologic malignancies, the hope brought by novel therapy strategies, and the potential for artificial intelligence to improve diagnostic accuracy.

Our top multiple myeloma (MM) content this year included research suggesting many patients still face poor prognoses despite advances, a case study of unique MM presentation, and research presented at the 2022 American Society of Hematology Annual Meeting.

In the phase 3 EV-302/KEYNOTE-A39 clinical trial, the antibody-drug conjugate enfortumab vedotin plus PD-1 inhibitor pembrolizumab nearly doubled both median overall survival and progression-free survival compared with chemotherapy.

Our most-read coverage from the Association of Community Cancer Centers (ACCC) 2023 Annual Meeting and Cancer Center Business Summit highlighted ongoing issues in oncology policy and practice.

Our most-read coverage from the 2023 European Society for Medical Oncology (ESMO) Congress included potentially practice-changing findings across a range of cancer types, including lung cancer, breast cancer, and urothelial carcinoma.